Page 6,011«..1020..6,0106,0116,0126,013..6,0206,030..»

Autism Training Solutions Partners with Arkansas Autism Medicaid Waiver

Posted: Published on December 5th, 2012

HONOLULU, Dec.4, 2012 /PRNewswire-iReach/ -- Arkansas Autism Partnership (AAP) has selected Autism Training Solutions (ATS) to provide online autism training to direct line staff, lead therapists and parents participating in Arkansas' Autism Medicaid Waiver Program. (Photo: http://photos.prnewswire.com/prnh/20121204/CG23977) Starting November 1, 2012, the twenty-five (25) agencies contracted to provide autism services through the Autism Medicaid Waiver Program will be given subscriptions to Autism Training Solutions' 40-hour training platform. The ATS program will cover different topics under the umbrella of Applied Behavior Analysis (ABA), including Discrete Trial Instruction, Naturalistic Teaching and Principles of Behavior. Agencies will also provide staff with up to 80 hours of hands-on training to further bridge the gap between knowledge and application. "We are excited to be part of such an important state initiative," stated Emaley McCulloch, Co-Founder and President of Autism Training Solutions. "By combining the ATS online training program with a hands-on training component, the state of Arkansas has created a standard of training that will allow children across Arkansas to uniformly receive a high quality of service." Autism Training Solutions (ATS) is the online education company dedicated to training professionals and paraprofessionals within the field of autism and related behavioral disabilities. Through a unique blend … Continue reading →

Comments Off on Autism Training Solutions Partners with Arkansas Autism Medicaid Waiver

Controversial Issues Facing the Clinician in Stroke Care – Video

Posted: Published on December 5th, 2012

Controversial Issues Facing the Clinician in Stroke Care New advances and trials are underway for treatment of acute stroke in relation to thrombolysis, devices to improve blood flow, and blood pressure lowering strategies. There are controversies surrounding these treatments, including why these newer techniques may or may not fail to improve acute stroke care. Using a case-based format, his lecture will provide the evidence for these controversies and offer best practices for stroke treatment for acute ischemic stroke (AIS) and recurrent stroke prevention.From:SMA TubeViews:2 0ratingsTime:36:07More inEducation Continued here: Controversial Issues Facing the Clinician in Stroke Care - Video … Continue reading →

Comments Off on Controversial Issues Facing the Clinician in Stroke Care – Video

Physicians at Pain Care Bring Hope to Hundreds of Pain Management Patients Who Previously Had None Through Use of a …

Posted: Published on December 5th, 2012

The doctors at Pain Care are changing the lives of their patients who have failed traditional therapies and were left with little to no hope of a normal lifestyle, but who are now able to enjoy an active lifestyle due to a new procedure called Spinal Cord Stimulation. Stockbridge, GA (PRWEB) December 05, 2012 In addition to its many physiological benefits, SCS provides valuable alternatives to traditional narcotic therapies. Dr. Vincent Galan, the medical director at Pain Care who has practiced in the Atlanta area for over 25 years, explains: Long-term narcotic usage has been shown to produce harmful side-effects which can lessen a persons quality-of-life. For that reason, we tend to steer patients toward interventional procedures like SCS for their pain relief. Additionally, SCS has been effective in many of my patients who have tried narcotic therapy without any success. "This is truly a revolutionary procedure and it is virtually unknown to the general public" continues Dr. Galan. Who is a candidate for a SCS? Anyone who suffers from neuropathic pain or pain stemming from damaged nerves. Once a patient is approved for the procedure, we first perform a trial procedure or a test drive as many patients describe … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Physicians at Pain Care Bring Hope to Hundreds of Pain Management Patients Who Previously Had None Through Use of a …

Elbit Imaging Ltd. Announces InSightec's ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of …

Posted: Published on December 5th, 2012

TEL AVIV, Israel, December 4, 2012 /PRNewswire/ -- Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today that on December 3, 2012, Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE:EMTC-M) (in which the Company holds approximately 90%), announced that InSightec Ltd. ("InSightec") (in which Elbit Medical holds approximately 64%, and 52.15% on a fully diluted basis) has been awarded the European CE mark for its transcranial focused ultrasound system, ExAblate Neuro, with respect to the treatment of neurological disorders in the brain, including essential tremor, Parkinson's disease and neuropathic pain. Treatment options for patients suffering from neurological disorders, who do not respond to drug treatments include deep brain stimulation, radiofrequency ablation and radiosurgery, which are invasive or involve ionizing radiation and are associated with recognized radiation risks and high risk of complications and side effects. As opposed to the above, InSightec elaborated, ExAblate Neuro offers a non-invasive treatment with no ionizing radiation by treating tissue deep in the brain through an intact skull. MR guided Focused ultrasound (MRgFUS) combines therapeutic acoustic ultrasound waves with continuous MRI guidance. The MRI enables physicians to visualize, plan, guide, monitor and control the treatment, while the ultrasound acoustic energy destroys the targeted … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Elbit Imaging Ltd. Announces InSightec's ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of …

InSightec's ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the …

Posted: Published on December 5th, 2012

ExAblate treatment is indicated for use for essential tremor, tremor dominant Parkinson's disease and neuropathic pain TIRAT CARMEL, Israel, Dec. 4, 2012 /PRNewswire/ -- InSightec Ltd. announced that its transcranial focused ultrasound system, ExAblate Neuro, has been awarded the European CE mark for the treatment of neurological disorders in the brain including essential tremor, Parkinson's disease and neuropathic pain. Millions of people suffer from neurological disorders which cause significant disability and negatively affect their quality of life and that of their caretakers. Treatment options for patients who do not respond to drug treatments include deep brain stimulation, radiofrequency ablation and radiosurgery which are invasive or involve ionizing radiation and are associated with recognized risks: high doses of ionizing radiation or high risk of complications and side effects including infection, bleeding and collateral brain tissue damage. Visit: http://www.insightec.com/ExAblate-Neuro-CE.html "ExAblate offers great potential for treating brain disorders. Because of its targeting accuracy, real time treatment monitoring and ability to provide non- invasive brain treatment, there is hope that many people who suffer from neurological diseases can benefit from this treatment." said Dr. Kobi Vortman, President of InSightec. "Results from the clinical studies showed that patients, many of whom who suffered for years … Continue reading →

Posted in Parkinson's Treatment | Comments Off on InSightec's ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the …

Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program

Posted: Published on December 5th, 2012

SUNNYVALE, Calif., Dec. 4, 2012 /PRNewswire/ --Amarantus Bioscience, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed former Super Bowl Champion Toi Cook to its Board of Advisors. Mr. Cook will work with Company management to engage the National Football League (NFL), NFL Players Association (NFLPA) and individual retired players to raise awareness and funding for Amarantus' Coalition for Concussion Treatment (#C4CT) campaign, including the Company's MANF collaboration with Banyan Biomarkers that yielded positive data in Q2/2012. "It's time to change the conversation about concussions and Traumatic Brain Injury in the NFL," said Toi Cook, Amarantus' newly appointed advisor. "We have been so focused on who is to blame for the rash of devastating results of brain injuries suffered while playing, that we have lost focus on the actual players who need help. Amarantus is working on breakthrough science that could ultimately treat concussions, brain injuries and their long-term side effects. This is the type of program that needs to be highlighted to the powers that be in the NFL and the NFLPA and we, as former players, … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program

United Water’s Lisette Provencher Elected to World Water Council’s Board of Governors

Posted: Published on December 5th, 2012

HARRINGTON PARK, N.J.--(BUSINESS WIRE)-- United Water announced today that Lisette Provencher, senior vice president, operations support, for United Water, has been elected to serve on the Board of Governors of the World Water Council. Bernard Guirkinger, Senior Executive Vice President of United Waters parent company SUEZ ENVIRONNEMENT was elected as an Alternate Representative for Ms. Provencher. The World Water Council, representing some 350 organizations in more than 70 countries, works to ensure water security. Ms. Provencher is one of 36 governors, drawn from 13 countries and six international and intergovernmental organizations. She was elected by majority vote from among 64 candidates and will serve until 2015, when the World Water Forum, an international triennial gathering, next convenes. Ms. Provencher succeeds Patrick Cairo, senior vice president, corporate development, of United Water, who served on the Board of Governors of the World Water Council for six years. The elections took place in November during the councils general assembly for which 240 participants had gathered in Marseille, France. Having focused during the past three years on increasing awareness, fostering dialogue and encouraging the emergence of solutions, the World Water Council is now moving forward in three strategic directions: water security for human essential … Continue reading →

Posted in MS Treatment | Comments Off on United Water’s Lisette Provencher Elected to World Water Council’s Board of Governors

Novartis’s Gilenya MS Patient Share Growth in Europe Likely Driven by Improved Product Satisfaction and Efficacy …

Posted: Published on December 5th, 2012

EXTON, Pa.--(BUSINESS WIRE)-- BioTrends Research Group, one of the worlds leading research and advisory firms for specialized biopharmaceutical issues, finds that Novartiss Gilenya captures 5.4 percent of those multiple sclerosis (MS) patients treated with disease-modifying agents (DMAs) in the EU5 (France, Germany, Italy, Spain, and the U.K.). This represents an increase from 2.3 percent share one year ago, with significant growth seen among relapsing remitting MS (RRMS), primary relapsing MS (PRMS) and secondary progressive MS (SPMS) patient segments. Consistent with this growth in patient share, neurologists rate their overall satisfaction with Gilenya and its performance on efficacy-related attributes, such as relapse rate reduction, long-term, sustained efficacy and clinical data support, significantly higher compared to 2011. However, it is important to highlight that neurologists rate Biogen Idec/lans Tysabri significantly higher on overall satisfaction and performance than all other commercially available DMAs, likely due to positive perceptions of Tysabris performance on efficacy-related attributes. TreatmentTrends: Multiple Sclerosis (EU) 2012 report also finds that the greatest percent of neurologists continue to voice a first-line preference for Biogen Idecs Avonex or a high dose/high frequency interferon (Merck Seronos Rebif for RRMS and Bayers Betaferon for progressive MS). However, compared to 2011, significantly more neurologists report … Continue reading →

Posted in MS Treatment | Comments Off on Novartis’s Gilenya MS Patient Share Growth in Europe Likely Driven by Improved Product Satisfaction and Efficacy …

Roger De Felippo, MD, Principal Investigator in The Saban Research Institute – Video

Posted: Published on December 5th, 2012

Roger De Felippo, MD, Principal Investigator in The Saban Research Institute Roger De Felippo, MD studies new uses of stem cells and other techniques for organ regeneration and cell therapeutics at Children's Hospital Los Angeles.From:childrensLAViews:1 0ratingsTime:01:34More inScience Technology Go here to read the rest: Roger De Felippo, MD, Principal Investigator in The Saban Research Institute - Video … Continue reading →

Posted in Stem Cell Research | Comments Off on Roger De Felippo, MD, Principal Investigator in The Saban Research Institute – Video

Stem Cell Research: Moving Forward

Posted: Published on December 5th, 2012

Stem Cell Research: Moving Forward The Role of Government 1 Presentation given on November 29, 2012From:thereveriepangViews:1 0ratingsTime:09:01More inEducation Visit link: Stem Cell Research: Moving Forward … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem Cell Research: Moving Forward

Page 6,011«..1020..6,0106,0116,0126,013..6,0206,030..»